As you may be aware, on December 27, 2019, Melinta announced that the Company had initiated voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code. We also announced that we reached an agreement with our senior lender that would allow Melinta to emerge from Chapter 11 on an expedited basis under new ownership and continue operating on sound financial footing. Our lender’s proposal to acquire the Company, however, remains subject to a Court-supervised competitive bidding process that could result in higher and better offers. Melinta and its advisors will evaluate any competing bids submitted to ensure the Company receives the highest and best offer for its business in connection with the Chapter 11 process. The closing of any transaction will be subject to Bankruptcy Court approval and the Company aims to complete this process by the end of the first quarter of 2020.

Most importantly – we want you to know that Melinta is not closing its doors. During this process, Melinta will continue to operate with no anticipated disruption to supply, distribution, promotion, or support of our antibiotics. Melinta’s restructuring under Chapter 11 is purely a financial one and we are confident that this process will secure new ownership of the business and the financial resources to support our portfolio and ensure our products continue to be available for your patients.

This site is intended for U.S. health care professionals only.

At presentation 05.11.17

08.02.17

To admit or not to admit?

Cellulitis: Physician Submitted Case

Lisa is an avid hiker. A simple blister developed into cellulitis. Read her story and why her physician chose ORBACTIV®.

Individual treatment results may vary.

INSURANCE VERIFICATION

Determine specific coverage for ORBACTIV® (oritavancin).

Learn More

CODING AND REIMBURSEMENT

ORBACTIV® permanent
J-code J2407 and additional guidance for providers.

Learn More

PATIENT ASSISTANCE

Information regarding access for qualifying patients in need.

Learn More

MECHANISM OF ACTION

Watch the Orbactiv® (oritavancin) mechanism of action video

ORBACTIV® has 3 mechanisms of action.

View the MOA video

REFERENCES:

  1. ORBACTIV® [package insert], Lincolnshire, IL: Melinta Therapeutics, Inc.; 2018.

INDICATION AND USAGE

ORBACTIV® (oritavancin) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and -resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV® and other antibacterial drugs, ORBACTIV® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Important Safety Information

Contraindications

Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after ORBACTIV® administration because the activated partial thromboplastin time (aPTT) test results are expected to remain falsely elevated for approximately 120 hours (5 days) after ORBACTIV® administration.

ORBACTIV® is contraindicated in patients with known hypersensitivity to ORBACTIV®.

Warnings and Precautions

Coagulation test interference: ORBACTIV® has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours, and ACT for up to 24 hours. ORBACTIV® has also been shown to elevate D-dimer concentrations up to 72 hours.

Hypersensitivity reactions, including anaphylaxis, have been reported with the use of antibacterial agents including ORBACTIV®. Discontinue infusion if signs of acute hypersensitivity occur. Monitor closely patients with known hypersensitivity to glycopeptides.

Infusion Related Reactions: Administer ORBACTIV® over 3 hours to minimize infusion-related reactions. Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of ORBACTIV®, including after the administration of more than one dose of ORBACTIV® during a single course of therapy. Stopping or slowing the infusion may result in cessation of these reactions.

Clostridium difficile-associated diarrhea: Evaluate patients if diarrhea occurs.

Concomitant warfarin use: ORBACTIV® has been shown to artificially prolong PT and INR for up to 12 hours. Patients should be monitored for bleeding if concomitantly receiving ORBACTIV® and warfarin.

Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.

Prescribing ORBACTIV® in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions (≥3%) in patients treated with ORBACTIV® were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.

See Full Prescribing Information

INDICATION

ORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and -resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).

www.orbactiv.com

This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue.

Ok
Cancel